Patents by Inventor Erwin Houtzager
Erwin Houtzager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160238600Abstract: Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.Type: ApplicationFiled: April 27, 2016Publication date: August 18, 2016Applicant: Merus B.V.Inventors: Hendricus Renerus Hoogenboom, Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20140317766Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: April 29, 2014Publication date: October 23, 2014Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20140314755Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: April 30, 2014Publication date: October 23, 2014Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Patent number: 8129178Abstract: The present invention relates to a bioreactor assembly containing a reactor frame that permits linear upscaling under identical conditions of culture volumes from two liters to thousands of liters. The bioreactor contains at least one rocking platforms being capable of holding at least one disposable bag adapted for receiving a total volume of at least 2 liters. The at least one platforms have a tray-like shape, that induces the fluid in the bag to move and form a wave-like motion. The at least one platforms are attached to the reactor frame and are positioned on top of each other along a vertical axis. In particular, the weight distribution of the rocking platforms is approximately in balance during rocking. The present invention further relates to methods using the bioreactor assembly.Type: GrantFiled: July 1, 2005Date of Patent: March 6, 2012Assignee: Millipore CorporationInventors: Erwin Houtzager, Sander Huurman
-
Patent number: 7901919Abstract: The invention relates to the field of generating helper phages and phage display libraries for the identification of binding molecules. The invention provide chimaeric phages having a coat comprising a protein mixture. The protein mixture comprises a fusion protein having a proteinaceous molecule fused to a functional form of a phage coat protein and a mutant form of the phage coat protein, wherein the mutant form is impaired in binding to a host cell receptor. The invention further provides new phage collections, novel helper phages and methods and means for producing chimaeric phages, infectious phages and helper phages.Type: GrantFiled: October 26, 2007Date of Patent: March 8, 2011Assignee: Crucell Holland B.V.Inventors: Erwin Houtzager, Ton Logtenberg, Cornelis Adriaan De Kruif
-
Publication number: 20100146647Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: October 19, 2009Publication date: June 10, 2010Applicant: Merus B. V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20100069614Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: June 29, 2009Publication date: March 18, 2010Applicant: Merus B.V.Inventors: Erwin Houtzager, Rui Daniel Pinto, Ton Logtenberg, Mark Throsby
-
Publication number: 20090017521Abstract: The invention relates to the field of generating helper phages and phage display libraries for the identification of binding molecules. The invention provide chimaeric phages having a coat comprising a protein mixture. The protein mixture comprises a fusion protein having a proteinaceous molecule fused to a functional form of a phage coat protein and a mutant form of the phage coat protein, wherein the mutant form is impaired in binding to a host cell receptor. The invention further provides new phage collections, novel helper phages and methods and means for producing chimaeric phages, infectious phages and helper phages.Type: ApplicationFiled: October 26, 2007Publication date: January 15, 2009Inventors: Erwin Houtzager, Ton Logtenberg, Cornelis Adriaan De Kruif
-
Patent number: 7329530Abstract: The invention relates to the field of generating helper phages and phage display libraries for the identification of binding molecules. The invention provide chimaeric phages having a coat comprising a protein mixture. The protein mixture comprises a fusion protein having a proteinaceous molecule fused to a functional form of a phage coat protein and a mutant form of the phage coat protein, wherein the mutant form is impaired in binding to a host cell receptor. The invention further provides new phage collections, novel helper phages and methods and means for producing chimaeric phages, infectious phages and helper phages.Type: GrantFiled: June 14, 2002Date of Patent: February 12, 2008Assignee: Crucell Holland B.V.Inventors: Erwin Houtzager, Ton Logtenberg, Cornelis Adriaan De Kruif
-
Publication number: 20070269888Abstract: The present invention relates to a bioreactor assembly comprising a reactor frame that permits linear upscaling under identical conditions of culture volumes from two liters to thousands of liters. The bioreactor comprises at least one rocking platforms being capable of holding at least one disposable bag adapted for receiving a total volume of at least 2 liters. Said at least one platforms have a tray-like shape, that induces the fluid in the bag to move and form a wave-like motion. Said at least one platforms are attached to the reactor frame and are positioned on top of each other along a vertical axis. In particular, the weight distribution of the rocking platforms is approximately in balance during rocking. The present invention further relates to methods using the bioreactor assembly.Type: ApplicationFiled: July 1, 2005Publication date: November 22, 2007Inventors: Erwin Houtzager, Sander Huurman
-
Publication number: 20060292634Abstract: Means and methods for generating binding peptide associated with a suitable core region are disclosed, the resulting proteinaceous molecule and uses thereof. A solution to the problems associated with the use of binding molecules over their entire range of use. Binding molecules can be designed to accommodate extreme conditions of use such as extreme temperatures or pH. Alternatively, binding molecules can be designed to respond to very subtle changes in the environment.Type: ApplicationFiled: May 19, 2006Publication date: December 28, 2006Applicant: CatchMabs B.V.Inventors: Erwin Houtzager, Irma Vijn, Peter Sijmons
-
Publication number: 20060177437Abstract: Described are means and methods for generating binding peptide associated with a suitable core region, the resulting proteinaceous molecule and uses thereof. The invention provides a solution to the problems associated with the use of binding molecules over their entire range of use. Binding molecules can be designed to accommodate extreme conditions of use, such as extreme temperatures or pH. Alternatively, binding molecules can be designed to respond to very subtle changes in the environment.Type: ApplicationFiled: December 9, 2005Publication date: August 10, 2006Applicant: CatchMabs B.V.Inventors: Erwin Houtzager, Wietse Willebrands, Guy de Roo, KeesJan Francoijs, Irma Vijn
-
Patent number: 7070926Abstract: A chimeric phage having a coat comprising a mixture of proteins. The mixture of proteins includes a fusion protein wherein a protein is fused to a functional form of a phage coat protein, and a mutant form of the phage coat protein characterized in that a phage having no wild type phage coat protein from which the mutant form is derived but having a coat comprising the mutant form and no copies of the functional form is less infectious than a phage comprising no wild type phage coat protein from which the mutant form is derived and having a coat comprising the mutant form and at least one copy of the functional form. Also, the associated phage collection comprising the chimaeric phage or an infectious phage containing at least one copy of a mutant form of a phage coat protein wherein the mutant form has lost the ability to mediate infection of a natural host by the infectious phage. Also a method for producing a phage particle.Type: GrantFiled: June 15, 2001Date of Patent: July 4, 2006Assignee: Crucell Holland B.V.Inventors: Erwin Houtzager, Ton Logtenberg, Cornelis A. de Kruif
-
Publication number: 20060140889Abstract: Provided are means and methods for applying a cosmetic substance to a desired target. The method comprises providing a conjugate of a proteinaceous substance having a specific affinity for the target molecule linked to a cosmetic substance, whereby the resulting connection between the cosmetic substance and the target molecule can be disrupted upon the presence of a chemical and/or physical signal.Type: ApplicationFiled: June 10, 2005Publication date: June 29, 2006Applicant: L-MAbs B.V.Inventors: Erwin Houtzager, Irma Vijn, Peter Sijmons, Grant Mudge, Addi Fadel
-
Publication number: 20050037427Abstract: Provided are means and methods for generating binding peptide associated with a suitable core region, the resulting proteinaceous molecule and uses thereof. The invention provides a solution to the problems associated with the use of binding molecules over their entire range of use. Binding molecules can be designed to accommodate extreme conditions of use such as extreme temperatures or pH. Alternatively, binding molecules can be designed to respond to very subtle changes in the environment.Type: ApplicationFiled: December 10, 2003Publication date: February 17, 2005Inventors: Erwin Houtzager, Irma Vijn, Cornelis Francoijs, Peter Sijmons
-
Publication number: 20050014261Abstract: The invention relates to the field of generating helper phages and phage display libraries for the identification of binding molecules. The invention provide chimaeric phages having a coat comprising a protein mixture. The protein mixture comprises a fusion protein having a proteinaceous molecule fused to a functional form of a phage coat protein and a mutant form of the phage coat protein, wherein the mutant form is impaired in binding to a host cell receptor. The invention further provides new phage collections, novel helper phages and methods and means for producing chimaeric phages, infectious phages and helper phages.Type: ApplicationFiled: June 14, 2002Publication date: January 20, 2005Inventors: Erwin Houtzager, Ton Logtenberg, Cornelis De Kruif
-
Publication number: 20030219829Abstract: The invention provides libraries comprising binding molecules adapted to expression in an expression organism, but also transferable to a human context without undergoing a change in conformation and/or build up. A method for producing a human monoclonal antibody includes: providing a library of binding molecules, the binding domain of which consists essentially of human heavy chain variable fragments in a functional format, selecting from the library at least one heavy chain variable fragment having a desired binding affinity, and inserting a nucleic acid encoding the heavy chain variable fragment into a nucleic acid encoding the complementary part of at least a heavy chain of the human monoclonal antibody, allowing for expression of the resulting heavy chain and for assembly of the heavy chain with a desired light chain, and producing a human monoclonal antibody.Type: ApplicationFiled: March 5, 2003Publication date: November 27, 2003Inventors: Ton Logtenberg, Erwin Houtzager
-
Publication number: 20030215914Abstract: Means and methods for generating binding peptide associated with a suitable core region are disclosed, the resulting proteinaceous molecule and uses thereof. A solution to the problems associated with the use of binding molecules over their entire range of use. Binding molecules can be designed to accommodate extreme conditions of use such as extreme temperatures or pH. Alternatively, binding molecules can be designed to respond to very subtle changes in the environment.Type: ApplicationFiled: December 10, 2002Publication date: November 20, 2003Inventors: Erwin Houtzager, Irma Maria Caecilia Vijn, Peter Christiaan Sijmons
-
Publication number: 20030108985Abstract: Proteinaceous molecules involved in molecular binding are disclosed. The binding molecules have a common structural core element that is provided with a desired affinity region. The core element and the desired affinity region can be adapted to bind to a wide range of molecules for a desired purpose. A method for identifying a binding molecule with an altered binding property and producing a nucleic acid for the identified binding molecule are also disclosed.Type: ApplicationFiled: December 10, 2001Publication date: June 12, 2003Inventors: Erwin Houtzager, Irma Maria Caecilia Vijn, Peter Christiaan Sijmons
-
Publication number: 20030054495Abstract: A chimeric phage having a coat comprising a mixture of proteins. The mixture of proteins includes a fusion protein wherein a protein is fused to a functional form of a phage coat protein, and a mutant form of the phage coat protein characterized in that a phage having no wild type phage coat protein from which the mutant form is derived but having a coat comprising the mutant form and no copies of the functional form is less infectious than a phage comprising no wild type phage coat protein from which the mutant form is derived and having a coat comprising the mutant form and at least one copy of the functional form. Also, the associated phage collection comprising the chimaeric phage or an infectious phage containing at least one copy of a mutant form of a phage coat protein wherein the mutant form has lost the ability to mediate infection of a natural host by the infectious phage. Also a method for producing a phage particle.Type: ApplicationFiled: June 15, 2001Publication date: March 20, 2003Inventors: Erwin Houtzager, Ton Logtenberg, Cornelis Adriaan de Kruif